Anavex Life Sciences Corp (AVXL)

[JB3729]

I received this from IR a week ago. It sounds like we will hear of more applications in the months ahead -


Thank you for your email and interest in Anavex Life Sciences Corp. (Nasdaq: AVXL).

The latest press release issued regard a patent related to ANAVEX 2-73 was issued on August 12, 2015. You may view it here: www.anavex.com/?news=anavex-receives-notice-of-allowance-for-u-s-patent-application-related-to-anavex-2-73.

Anavex is extremely focused on the patent position of ANAVEX 2-73 and related drugs. The company is engaged in a rigorous patent filing and prosecution effort to protect Anavex in all forms, methods of use, and methods of production. Patent applications are necessarily published 18 months from filing. When published, the investor community will be free to review these patent applications. At such time, the investor community will be able to evaluate the scope of patent protection sought and granted.

Patents enjoy a minimum term of 20 years from the earliest claimed filing date. For various reasons, this term may be extended for up to five years by the Patent Office.

Please do not hesitate to contact our office if we can be of further assistance.

On behalf of Anavex Life Sciences Corp.,

Investor Relations
Toll Free (North America): 1 [phone]
Outside North America: [phone]
Fax: [phone]
[e-mail]